| Patient | Nelson Mandela |
|---|---|
| Date of birth | 1943-07-18 |
| Identifiers | MRN HR-ML021-SYN; SSN (made up) 000-21-6718 |
| Document date | 2026-03-10 |
| Author | Thandiwe Mokoena, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
The patient attends this visit for first visit after a biopsy diagnosis of localized prostate cancer: risk group, staging, baseline before treatment, and radiation oncology referral. [S]
PSA: 6.4 ng/mL (high); Total testosterone: 412 ng/dL; Hemoglobin: 14.1 g/dL; White cell count: 5.8 10*3/uL; Platelets: 226 10*3/uL; Sodium: 140 mmol/L; Potassium: 4.4 mmol/L; Fasting glucose: 94 mg/dL; Creatinine: 1.08 mg/dL; eGFR: 69 mL/min/1.73 m²; Calcium: 9.4 mg/dL; ALT: 18 U/L; Alkaline phosphatase: 74 U/L; Albumin: 4.1 g/dL; Hemoglobin A1c: 5.5%; Total cholesterol: 184 mg/dL; HDL cholesterol: 52 mg/dL; LDL cholesterol: 112 mg/dL; Triglycerides: 98 mg/dL; 25-hydroxyvitamin D: 26 ng/mL (low); PHQ-9: 4; IPSS total (0 to 35): 7. [S]
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-10 | Body height | 183 | cm | S |
| 2026-03-10 | Body weight | 80.2 | kg | S |
| 2026-03-10 | Body mass index (BMI) [Ratio] | 23.9 | kg/m2 | S |
| 2026-03-10 | Systolic blood pressure | 132 | mm[Hg] | S |
| 2026-03-10 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-03-10 | Heart rate | 68 | /min | S |
| 2026-03-10 | Respiratory rate | 14 | /min | S |
| 2026-03-10 | Body temperature | 36.6 | Cel | S |
| 2026-03-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-10 | Prostate specific Ag [Mass/volume] in Serum or Plasma | 6.4 | ng/mL | <=4 ng/mL | High | S |
| 2026-03-10 | Testosterone [Mass/volume] in Serum or Plasma | 412 | ng/dL | 264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivation | Normal | S |
| 2026-03-10 | Hemoglobin [Mass/volume] in Blood | 14.1 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-03-10 | Leukocytes [#/volume] in Blood by Automated count | 5.8 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-03-10 | Platelets [#/volume] in Blood by Automated count | 226 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-03-10 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-10 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-10 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-03-10 | Creatinine [Mass/volume] in Serum or Plasma | 1.08 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-03-10 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 69 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-03-10 | Calcium [Mass/volume] in Serum or Plasma | 9.4 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-03-10 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 18 | U/L | 7-55 U/L | Normal | S |
| 2026-03-10 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 74 | U/L | 40-129 U/L | Normal | S |
| 2026-03-10 | Albumin [Mass/volume] in Serum or Plasma | 4.1 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-03-10 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.5 | % | <=5.6% | Normal | S |
| 2026-03-10 | Cholesterol [Mass/volume] in Serum or Plasma | 184 | mg/dL | <=200 mg/dL | Normal | S |
| 2026-03-10 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 52 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-03-10 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 112 | mg/dL | <=129 mg/dL | Normal | S |
| 2026-03-10 | Triglyceride [Mass/volume] in Serum or Plasma | 98 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-03-10 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 26 | ng/mL | 30-100 ng/mL | Low | S |
| 2026-03-10 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 2026-03-10 | International Prostate Symptom Score [IPSS] | 7 | {score} | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Adenocarcinoma of the prostate, NCCN unfavorable intermediate risk: cT1c, Grade Group 3 (Gleason 4+3), PSA 6.4 ng/mL, 3 of 14 cores, found after a rising PSA; synthetic modern detail linked to his publicly announced prostate cancer | active | confirmed | C61 | S — Synthetic grade, PSA, core count, stage, and risk group; the PSA rise, the biopsy-proven localized cancer that was not high grade, hormone therapy, and curative radiotherapy are from his doctors' and spokeswoman's public statements (D). |
| Hormone-sensitive prostate cancer | active | confirmed | Z19.1 | S — Synthetic status in the modern episode. |
| History of pulmonary tuberculosis, treated, with no symptoms since | resolved | confirmed | Z86.11 | S — The 1988 tuberculosis is documented (D); the coding and the statement that it has not recurred are synthetic. |